NCT03333694: A trial that was reported late by Novartis Pharmaceuticals
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03333694 |
|---|---|
| Title | A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 15, 2017 |
| Completion date | Nov. 1, 2018 |
| Required reporting date | Nov. 1, 2019, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2020 |
| Days late | None |